Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21)

Archive ouverte

Burlet, Bénédicte | Ramla, Selim | Fournier, Cyril | Abrey-Recalde, Maria Jimena | Sauter, Camille | Chrétien, Marie-Lorraine | Rossi, Cédric | Duffourd, Yannis | Ragot, Sylviane | Buriller, Céline | Tournier, Benjamin | Chapusot, Caroline | Nadal, Nathalie | Racine, Jessica | Guy, Julien | Bailly, François | Martin, Laurent | Casasnovas, Olivier | Bastie, Jean-Noël | Caillot, Denis | Albuisson, Juliette | Broccardo, Cyril | Thieblemont, Catherine | Delva, Laurent | Maynadié, Marc | Aucagne, Romain | Callanan, Mary

Edité par CCSD -

International audience. Diagnosis of B-cell chronic lymphocytic leukemia (B-CLL) is usually straightforward, involving clinical, immunophenotypic (Matutes score), and (immuno)genetic analyses (to refine patient prognosis for treatment). CLL cases with atypical presentation (e.g., Matutes ≤ 3) are also encountered, and for these diseases, biology and prognostic impact are less clear. Here we report the genomic characterization of a case of atypical B-CLL in a 70-yr-old male patient; B-CLL cells showed a Matutes score of 3, chromosomal translocation t(14;18)(q32;q21) ( BCL2/IGH ), mutated IGHV , deletion 17p, and mutations in BCL2 , NOTCH1 (subclonal), and TP53 (subclonal). Quite strikingly, a novel PAX5 mutation that was predicted to be loss of function was also seen. Exome sequencing identified, in addition, a potentially actionable BRAF mutation, together with novel somatic mutations affecting the homeobox transcription factor NKX2-3 , known to control B-lymphocyte development and homing, and the epigenetic regulator LRIF1 , which is implicated in chromatin compaction and gene silencing. Neither NKX2-3 nor LRIF1 mutations, predicted to be loss of function, have previously been reported in B-CLL. Sequencing confirmed the presence of these mutations together with BCL2 , NOTCH1 , and BRAF mutations, with the t(14;18)(q32;q21) translocation, in the initial diagnostic sample obtained 12 yr prior. This is suggestive of a role for these novel mutations in B-CLL initiation and stable clonal evolution, including upon treatment withdrawal. This case extends the spectrum of atypical B-CLL with t(14;18)(q32;q21) and highlights the value of more global precision genomics for patient follow-up and treatment in these patients.

Consulter en ligne

Suggestions

Du même auteur

Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia

Archive ouverte | Sauter, Camille | CCSD

International audience. Arginine methylation is catalyzed by protein arginine methyltransferases (PRMTs) and is involved in various cellular processes, including cancer development. PRMT2 expression is increased in ...

Ibrutinib, Obinutuzumab And Venetoclax In Relapsed and Untreated Patients with Mantle-Cell Lymphoma, a phase I/II trial

Archive ouverte | Le Gouill, Steven | CCSD

International audience. Ibrutinib, obinutuzumab plus venetoclax demonstrate synergy in pre-clinical models of mantle-cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multi-center prospective phase I/II trial, ...

Calreticulin Mutations in Myeloproliferative Neoplasms: Comparison of Three Diagnostic Methods

Archive ouverte | Park, Ji-Hye | CCSD

International audience. Calreticulin (CALR) mutations have recently been reported in 70-84% of JAK2V617F-negative myeloproliferative neoplasms (MPN), and this detection has become necessary to improve the diagnosis ...

Chargement des enrichissements...